Heron Therapeutics, Inc. (HRTX)
After hours:
| Previous close | 3.1000 |
| Open | 3.1500 |
| Bid | 3.0100 x 700 |
| Ask | 3.0800 x 1000 |
| Day's range | 3.0300 - 3.1600 |
| 52-week range | 0.5000 - 3.9300 |
| Volume | |
| Avg. volume | 2,364,916 |
| Market cap | 459.492M |
| Beta (5Y monthly) | 1.81 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -0.5500 |
| Earnings date | 12 Aug 2024 - 16 Aug 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 6.75 |
Simply Wall St.While shareholders of Heron Therapeutics (NASDAQ:HRTX) are in the black over 1 year, those who bought a week ago aren't so fortunate
Passive investing in index funds can generate returns that roughly match the overall market. But investors can boost...
PR NewswireHeron Therapeutics Announces the Inclusion of ZYNRELEF® as a Qualifying Product Under the Proposed 2025 Non-Opioid Policy for Pain Relief Under the OPPS and the ASC Payment System
Heron Therapeutics, Inc. (Nasdaq: HRTX) ("Heron" or the "Company"), a commercial-stage biotechnology company, today announced that ZYNRELEF® (bupivacaine and meloxicam) is included in the proposed 2025 Non-Opioid Policy for Pain Relief under the Medicare hospital Outpatient Prospective Payment System ("OPPS") and the Medicare Ambulatory Surgical Center ("ASC") payment system (the "Proposed Rule") as a qualifying product effective April 1, 2025. This Proposed Rule for payment within hospital outp
ZacksHeron Therapeutics (HRTX) Upgraded to Strong Buy: Here's What You Should Know
Heron Therapeutics (HRTX) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
